Valuation: Satellos Bioscience Inc.

Market Cap 165M 144M 133M 124M 234M 15.59B 240M 1.6B 619M 7.69B 619M 606M 26.71B P/E 2026 *
-4.62x
P/E 2027 * -4.94x
Enterprise Value 71.28M 62.41M 57.56M 53.77M 101M 6.74B 104M 692M 267M 3.32B 268M 262M 11.54B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
93.51%
Yield 2026 *
-
Yield 2027 * -
1 day+10.29%
1 week+38.04%
Current month+11.39%
1 month+16.70%
3 months+30.66%
6 months+39.93%
Current year+42.05%
1 week 7.76
Extreme 7.76
11.51
1 month 7.76
Extreme 7.76
11.51
Current year 7.67
Extreme 7.67
18.98
1 year 6.36
Extreme 6.36
18.98
3 years 3.48
Extreme 3.48
18.98
5 years 2.58
Extreme 2.58
22.8
10 years 2.58
Extreme 2.58
22.8
Manager TitleAgeSince
Chief Executive Officer 70 01/03/2018
Chief Tech/Sci/R&D Officer - 01/05/2018
Director of Finance/CFO - 01/09/2023
Director TitleAgeSince
Director/Board Member 76 29/06/2023
Chairman 59 01/07/2018
Director/Board Member 56 14/11/2025
Date Insider Type Main position Quantity % Market Cap.
06-18Buy

Director

15,000 0.0720%
04-07Option

Founder

108,630 0.7027%
04-07Buy

Director

4,500 0.0291%
Change 5-day change 1-year change 3-year change Capi.($)
+10.29%+38.04%+61.64%+91.33% 150M
+0.13%+1.50%+63.86%+123.95% 55.63B
+6.76%+22.83%+91.66%+101.42% 52.25B
+3.33%+3.71%-11.68%-11.82% 23.07B
+1.32%+9.33%+5.28%+419.80% 22.41B
+6.78%+14.47%+40.28%-6.67% 17.32B
+0.97%+5.01%+31.23%-32.10% 15.94B
-0.89%+4.57%+24.30%+185.83% 13.77B
+9.96%+19.81%+157.65%+320.70% 13.47B
+4.21%+4.76%+33.21% - 12.43B
Average +4.29%+8.67%+49.74%+132.49% 22.64B
Weighted average by Cap. +3.42%+7.63%+54.17%+128.93%

Financials

2026 *2027 *
Net sales - -
Net income -46.27M -40.51M -37.36M -34.9M -65.73M -4.37B -67.19M -449M -174M -2.16B -174M -170M -7.49B -57.06M -49.96M -46.08M -43.04M -81.06M -5.39B -82.86M -554M -214M -2.66B -214M -210M -9.24B
Net Debt -93.65M -82M -75.63M -70.65M -133M -8.85B -136M -909M -351M -4.37B -352M -344M -15.16B -111M -97.49M -89.92M -84M -158M -10.53B -162M -1.08B -418M -5.19B -418M -409M -18.03B
Logo Satellos Bioscience Inc.
Satellos Bioscience Inc. is a Canada-based clinical-stage drug development company. The Company is focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, the Company has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. It is also leveraging its proprietary discovery platform MyoReGenX to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process.
Employees
20
Date Price Change Volume
29/06/26 CA$11.25 +10.29% 74,298
26/06/26 CA$10.20 +6.03% 10,782
25/06/26 CA$9.620 +21.31% 27,902
24/06/26 CA$7.930 +0.51% 6,244
23/06/26 CA$7.890 -1.50% 15,198
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
11.25CAD
Average target price
15.33CAD
Spread / Average Target
+36.30%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MSCL Stock